Switch theme
Sign up to access all valuation multiples
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. The segments of the company are Pharmaceutical Manufacturing, Trading and Distribution services, and Healthcare Services, out of which the company derives maximum revenue from the Pharmaceutical Manufacturing segment. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco, and Algeria.
1986
n/a
LTM Revenue $465M
LTM EBITDA $68.9M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SPIMACO - ADDWAEIH has a last 12-month revenue (LTM) of $465M and a last 12-month EBITDA of $68.9M.
In the most recent fiscal year, SPIMACO - ADDWAEIH achieved revenue of $449M and an EBITDA of $67.4M.
SPIMACO - ADDWAEIH expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SPIMACO - ADDWAEIH valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $465M | XXX | $449M | XXX | XXX | XXX |
| Gross Profit | $227M | XXX | $223M | XXX | XXX | XXX |
| Gross Margin | 49% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $68.9M | XXX | $67.4M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $46.4M | XXX | $42.1M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $17.5M | XXX | $6.5M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $368M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SPIMACO - ADDWAEIH's stock price is SAR 25 (or $7).
SPIMACO - ADDWAEIH has current market cap of SAR 3.0B (or $795M), and EV of SAR 4.2B (or $1.1B).
See SPIMACO - ADDWAEIH trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $795M | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SPIMACO - ADDWAEIH has market cap of $795M and EV of $1.1B.
SPIMACO - ADDWAEIH's trades at 2.5x EV/Revenue multiple, and 16.6x EV/EBITDA.
Equity research analysts estimate SPIMACO - ADDWAEIH's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SPIMACO - ADDWAEIH has a P/E ratio of 45.5x.
See valuation multiples for SPIMACO - ADDWAEIH and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $795M | XXX | $795M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 16.3x | XXX | 16.6x | XXX | XXX | XXX |
| EV/EBIT | 24.2x | XXX | 26.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 45.5x | XXX | 121.4x | XXX | XXX | XXX |
| EV/FCF | 43.6x | XXX | -9.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSPIMACO - ADDWAEIH's last 12 month revenue growth is 9%
SPIMACO - ADDWAEIH's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
SPIMACO - ADDWAEIH's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SPIMACO - ADDWAEIH's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SPIMACO - ADDWAEIH and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 31% | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 24% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SPIMACO - ADDWAEIH acquired XXX companies to date.
Last acquisition by SPIMACO - ADDWAEIH was XXXXXXXX, XXXXX XXXXX XXXXXX . SPIMACO - ADDWAEIH acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SPIMACO - ADDWAEIH founded? | SPIMACO - ADDWAEIH was founded in 1986. |
| Where is SPIMACO - ADDWAEIH headquartered? | SPIMACO - ADDWAEIH is headquartered in Saudi Arabia. |
| Is SPIMACO - ADDWAEIH publicy listed? | Yes, SPIMACO - ADDWAEIH is a public company listed on SAU. |
| What is the stock symbol of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH trades under 2070 ticker. |
| Who are competitors of SPIMACO - ADDWAEIH? | Similar companies to SPIMACO - ADDWAEIH include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's current market cap is $795M |
| What is the current revenue of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's last 12 months revenue is $465M. |
| What is the current revenue growth of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of SPIMACO - ADDWAEIH? | Current revenue multiple of SPIMACO - ADDWAEIH is 2.4x. |
| Is SPIMACO - ADDWAEIH profitable? | Yes, SPIMACO - ADDWAEIH is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's last 12 months EBITDA is $68.9M. |
| What is SPIMACO - ADDWAEIH's EBITDA margin? | SPIMACO - ADDWAEIH's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of SPIMACO - ADDWAEIH? | Current EBITDA multiple of SPIMACO - ADDWAEIH is 16.3x. |
| What is the current FCF of SPIMACO - ADDWAEIH? | SPIMACO - ADDWAEIH's last 12 months FCF is $25.7M. |
| What is SPIMACO - ADDWAEIH's FCF margin? | SPIMACO - ADDWAEIH's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of SPIMACO - ADDWAEIH? | Current FCF multiple of SPIMACO - ADDWAEIH is 43.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
